Background: Ovarian cancer ranks among the top causes of cancer-related deaths in women worldwide [1]. The conventional treatment for ovarian cancer involves surgery and chemotherapy, typically using a combination of paclitaxel and carboplatin [2]. However, despite the initial positive response to this treatment regimen, the development of treatment resistance has emerged as a significant challenge in managing ...